Bethanechol Chloride Tablets
Lannett announced that it has received approval from the USFDA on its Abbreviated New Drug Application for Bethanechol Chloride Tablets in 5 mg, 10 mg, 25 mg, and 50 mg, the generic equivalent of Urecholine(R) Tablets marketed by Odyssey Pharma. Bethanechol Chloride is indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention.
Bupropion Hydrochloride extended-release tablets
Actavis Group, the international generic pharmaceuticals company, today announced that it has received two separate approvals from the USFDA to market Bupropion Hydrochloride extended-release tablets (SR). Distribution of the products will commence immediately. Bupropion Hydrochloride extended-release tablets (SR), available in 150mg strength, are the generic equivalent of Wellbutrin SR(R) and are indicated for the treatment of major depressive disorder.
